One‐year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 <scp>U/ml</scp> compared with 100 <scp>U/ml</scp> in people with type 2 diabetes using basal plus meal‐time insulin: the <scp>EDITION 1</scp> 12‐month randomized trial, including 6‐month extension

C. Riddle, Matthew; Yki‐Järvinen, Hannele; B. Bolli, Geremia; Ziemen, M.; Muehlen-Bartmer, Isabel; Cissokho, S; Home, Philip

doi:10.1111/dom.12472

Public

One‐year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal‐time insulin: the EDITION 1 12‐month randomized trial, including 6‐month extension

Published in Diabetes Obesity and Metabolism • Apr 2, 2015

Authors:

Matthew C. Riddle

Hannele Yki‐Järvinen

Geremia B. Bolli

Abstract

AIMS: To evaluate the maintenance of efficacy and safety of insulin glargine 300 U/ml (Gla-300) versus glargine 100 U/ml (Gla-100) in people with type 2 diabetes mellitus (T2DM) using basal plus meal-time insulin for 12 months in the EDITION 1 trial. METHODS: EDITION 1 was a multicentre, randomized,...

Subject

Insulin glargine

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!